NLRP3 and myocardial infarction: The failure to reproduce beneficial effects from previous preclinical studies in small and large animal models therefore again underlines the importance of further research and repeated testing with different NLRP3-inflammasome inhibitors, dosages and routes of administration in clinically relevant large animal models before heading to the clinical MI setting.